Composition, methods and uses
Assignee4E Therapeutics, Inc.
InventorsJohan Patrik Ernfors, Jie Su, Mingdong Zhang, Jussi Antero Kupari
Life of this patent
Estimating the term…
Abstract
The present disclosure relates to type I interferon inhibitors for use in treating or preventing pain associated with Rheumatoid Arthritis (RA) in a patient, related uses and kits, and methods for identifying a patient who has such pain and is in need of treatment with such an inhibitor.
Claims38
A method of treating or preventing pain associated with Rheumatoid Arthritis in a patient, comprising a step of administering a type I interferon inhibitor to the patient.
The method according to any preceding claim, wherein the pain is not neuropathic pain or neuroplastic pain.
The method according to any preceding claim, wherein the pain is chronic pain;
- for example, pain that is present for three months or more, or six months or more, or twelve months or more.
The method according to any preceding claim, wherein the pain is one or more selected from the group consisting of:
- pain hypersensitivity;
- allodynia;
- hyperalgesia;
- and arthralgia.
The method according to any preceding claim, wherein the pain is associated with and/or caused by:
- systemic inflammation;
- and/or
- local inflammation;
- and/or
- clinical inflammation.
The method according to any preceding claim, wherein the pain is not associated with and/or caused by Rheumatoid Arthritis inflammatory disease activity.
The method according to any preceding claim, wherein the pain is at an affected joint and/or opposite parts of an affected joint and/or cephalic parts of an affected joint and/or caudal parts of an affected joint.
The method according to any preceding claim, wherein the type I interferon inhibitor does not prevent or treat an inflammatory disease with increased type I interferon signalling.
The method according to any preceding claim, wherein:
- the pain is present along with disease inflammation;
- and/or
- the pain is present after the remission of disease inflammation.
The method according to any preceding claim, wherein the patient has received, or is receiving, pain treatment, but the pain persists and/or recurs and/or progresses.
The method according to any preceding claim, wherein the pain is associated with and/or caused by increased type I interferon signalling in the patient.
The method according to any preceding claim, wherein the type I interferon is selected from the group comprising:
- Interferon-alpha;
- Interferon-beta.
The method according to any preceding claim, wherein the pain is associated with increased number and/or activity of one or more active sensory neuron in the patient;
- preferably increased number and/or activity of one or more active nociceptor of the patient.
The method according to any preceding claim, wherein the type I interferon inhibitor:
- prevents or reduces type I interferon intracellular signalling in the patient;
- prevents or reduces levels of type I interferons in the patient;
- prevents or reduces activation of type I interferon receptors in the patient;
- prevents or reduces expression of one or more type I interferon-stimulated gene in the patient;
- and/or
- induces and/or increases expression of one or more type I interferon-repressed gene in the patient.
The method according to any preceding claim, wherein the type I interferon inhibitor is selected from the group consisting of:
- an MNK inhibitor (such as an MNK1 and/or MNK2 inhibitor), an IFNAR1 inhibitor, an IFNAR2 inhibitor, a TYK2 inhibitor, a type I interferon neutraliser, and a eukaryotic translation initiation factor 4E (eIF4E) inhibitor.
The method according to any preceding claim, wherein the type I interferon inhibitor is selected from the group consisting of:
- a small molecule, an antibody, an antibody part thereof, an antibody mimetic, a decoy receptor, a receptor body, and a vaccine.
The method according to any preceding claim, wherein the type I interferon inhibitor is selected from the group consisting of:
- deucravacitinib, anifrolumab, NDI-034858, NDI-031232, NDI-031301, NDI-031407, ESK-001, VTX-958, ICP-488, ropsacitinib, and GLPG3667.
A pharmaceutical composition comprising a type I interferon inhibitor and one or more therapeutic agent for treating pain associated with Rheumatoid Arthritis in a patient, and/or one or more therapeutic agent for treating Rheumatoid Arthritis, in combination with a pharmaceutically-acceptable carrier, diluent or excipient.
A method of treating or preventing pain associated with Rheumatoid Arthritis in a patient, comprising administering to the patient a type I interferon inhibitor and one or more therapeutic agent for treating pain associated with Rheumatoid Arthritis in a patient, and/or one or more therapeutic agent for treating Rheumatoid Arthritis.
A kit comprising a type I interferon inhibitor and one or more therapeutic agent for treating Rheumatoid Arthritis.
A method for identifying a patient who has pain associated with Rheumatoid Arthritis and is in need of treatment with a type I interferon inhibitor, the method comprising the steps of:
- (a) providing a test sample from a patient who has pain associated with Rheumatoid Arthritis;
- (b) determining the level of type I interferon signalling in the test sample;
- and
- (c) identifying the patient as one in need of treatment with a type I interferon inhibitor on the basis of the determination in Step (b).
Dependencies are inferred from the claim text.